Important note
This AI stock analysis for Amgen is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
Amgen - AI Stock Analysis
Analysis generated November 26, 2024
Amgen Inc. is a leading biotechnology company that develops and manufactures human therapeutics. With a broad portfolio that includes treatments for cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses, Amgen is well-positioned in the biopharmaceutical sector. The company has a strong commitment to research and development, and it currently has multiple products in various stages of development. Amgen operates globally, with a presence in numerous countries, and is headquartered in Thousand Oaks, California.
Fundamental Analysis
Amgen reported a revenue of $8.5 billion for the last quarter. This is a slight decrease of 0.21% compared to the previous quarter, indicating a potential concern for short-term performance. However, compared to the same quarter last year, revenue increased by 34.41%, showcasing strong year-over-year growth.
Net income for the last quarter was $2.83 billion. This figure represents a significant increase of 279.36% compared to the previous quarter, indicating substantial short-term growth. On a year-over-year basis, net income increased by 63.58%, reinforcing the positive growth trajectory.
The EBITDA for the last quarter was $5.08 billion, reflecting an increase of 81.19% from the previous quarter and a year-over-year increase of 49.37%. These figures demonstrate strong operating performance and efficient cost management.
The current Price-to-Earnings (P/E) ratio stands at 37.62. This high P/E ratio may indicate potential overvaluation, which is a bearish sign for investors. A high P/E ratio suggests that the stock price is relatively high compared to earnings, raising caution about future growth expectations.
Technical Analysis
Amgen's stock is currently priced at $294.00. This represents a decrease of 6.50% over the past month, which could be concerning for short-term investors. However, over the past year, the stock price has increased by 14.62%, indicating a positive long-term trend.
The 10-day Simple Moving Average (SMA10) is $288.94, which is higher than the previous SMA10 of $287.68. This indicates a potential upward trend in price movement.
The Relative Strength Index (RSI) is 71.1. This is above the threshold of 70, signaling that the stock may be overbought, potentially indicating a bearish condition and the possibility of a pullback in the near future.
Alternative Data Analysis
Job postings and employee sentiment are stable, with Amgen having 664 open positions. This stability indicates a steady operational environment.
Customer acquisition metrics show positive trends, with an estimated 770,000 visitors to their website, up by 45% in the last couple of months. This increase suggests growing customer interest and a potential rise in sales.
Customer engagement data is mixed. On Instagram, Amgen has 27,000 followers, up by 5%, indicating increased interest. Conversely, on Twitter, the number of followers has decreased by 1% to 120,000, suggesting a slight decline in engagement on that platform.
The AltIndex AI score for Amgen is 54, which signals a "Hold" recommendation. This score reflects a balanced view based on a combination of fundamental, technical, and alternative data analyses.
Conclusion
Amgen's recent performance presents a mixed bag of signals for investors. The company has demonstrated impressive year-over-year growth in revenue, net income, and EBITDA. However, a high P/E ratio raises some concerns about potential overvaluation. On the technical analysis front, despite a recent stock price drop, long-term trends remain positive. The slight decrease in Twitter followers suggests a small drop in customer engagement on that platform.
Taking all factors into account, including the AltIndex AI score of 54, which suggests holding the stock, the current recommendation for Amgen's stock is to hold. Investors may want to monitor market conditions and company performance closely, especially looking for signs of consistent growth and changes in valuation metrics.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
